MAbs largest class of biotherapeutics

Monoclonal antibodies (MAbs) were the fastest growing segment in the global pharmaceutical market in 2010, when the global MAb market was worth $43 billion while the rest of the biologics market was approximately $108 billion, according to a new report from GBI Research.

Application of MAbs ranges from various oncology indications to autoimmune diseases. Gradually, MAbs are beginning to pave their way into the treatment of central nervous system (CNS) disorders such as Alzheimer’s disease and metabolic disorders such as diabetes. The first Food and Drug Administration-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab) in 1986. This drug found use in solid organ transplant recipients who became steroid resistant

MAb successes